Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 PSMA PET/MR Study of SBRT With Prostate Cancer

Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the prostate
* tumor clinical stage cT1-3N0M0 according to AJCC TNM 2017
* Without any treatment of prostate cancer including radiotherapy, ADT, chemotherapy, focal treatment, etc.
* With the examination of Ga-68 PSMA PET/MR
* International Prostate Symptom Score(IPSS）\<15 (alpha blockers allowed), without severe urethral obstruction symptoms
* ECOG performance status 0-2
* Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures

Exclusion Criteria:

* Prior pelvic RT
* A tumor located at less than 3 mm from the urethra or rectum when measured at the MRI
* Tumor clinical stage cT4, with metastases including bone, lymph nodes or organ metastasis
* Histologically confirmed neuroendocrine tumor or small cell carcinoma of the prostate
* Severe or active co-morbidity likely to impact on the advisability of SBRT like severe liver or kidney dysfunction, etc.
* Patients with other malignancies, or acute or other severe infections, with ulcerative colitis, inflammatory bowel disease, etc.
* Patients who have participated in other clinical trials for less than three months
* Patients have acute prostatitis or chronic prostatitis with urinary symptoms
* Urine routine indicates obvious urinary system infection and no significant improvement after anti-infective treatment, or conversion to recurrent urinary system infection
* Unsuitable to participate in this clinical trial judged by the investigator